CSF3 and breast carcinoma: Use of G-CSF prophylaxis varied by cancer type and was greatest among patients with breast cancer and NHL who, consistent with standard of care [11, 25, 26], more commonly received chemotherapy regimens with intermediate or high FN risk (breast cancer: 56.3%; NHL: 68.1%).